Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
Add more filters










Database
Language
Publication year range
1.
Neuromodulation ; 25(8): 1086-1096, 2022 Dec.
Article in English | MEDLINE | ID: mdl-35688702

ABSTRACT

OBJECTIVE: Overactive bladder (OAB) is a condition that has physical, social, psychosocial, and financial impacts. Transcutaneous tibial nerve stimulation (TTNS) is a modality that stimulates the nerve root fibers of L5-S3, the same spinal segments of the parasympathetic nervous system as the bladder. This scoping review aims to identify current literature available on the feasibility and outcomes of TTNS as a first-line treatment option for OAB. MATERIALS AND METHODS: A scoping review of six electronic data bases was performed to identify full-text articles from 2015 that explored the impact of TTNS on OAB and bladder dysfunction in people aged >18 years. RESULTS: A total of 15 articles met the inclusion criteria. TTNS was compared with sham treatment, parasacral stimulation, pelvic floor muscle training (PFMT), anticholinergic medication, and percutaneous tibial nerve stimulation (PTNS). Heterogeneity in treatment application and parameters existed, with variations in treatment duration, frequency of use, and treatment settings such as pulse width (µs) and frequency (Hz). Results indicated that TTNS has efficacy equal to PFMT and PTNS in the management of OAB; however, it is not as efficacious as anticholinergic medication. CONCLUSIONS: TTNS is a promising first-line management option for people with OAB, particularly in the older population and for those with neurogenic bladder. It can provide symptomatic relief from urinary incontinence, frequency, urgency, and nocturia, while avoiding the bothersome side effects of more invasive or pharmaceutical therapies. Heterogeneity in treatment parameters limits generalizability and translation of the most appropriate clinical application and should be considered in future trials.


Subject(s)
Transcutaneous Electric Nerve Stimulation , Urinary Bladder, Overactive , Humans , Urinary Bladder, Overactive/therapy , Treatment Outcome , Transcutaneous Electric Nerve Stimulation/methods , Tibial Nerve , Cholinergic Antagonists
2.
Vaccine ; 36(15): 1990-1995, 2018 04 05.
Article in English | MEDLINE | ID: mdl-29525277

ABSTRACT

European badgers (Meles meles) are a wildlife reservoir for Mycobacterium bovis (M. bovis) in parts of England, Wales and Ireland, constituting a potential source of tuberculosis (TB) infection for cattle. Vaccination of badgers against TB is one of the tools available for helping reduce the prevalence of bovine TB in badgers, made possible by the licensing in 2010 of Bacillus Calmette-Guérin (BCG) vaccine for intramuscular administration to badgers (BadgerBCG). However, practical limitations associated with administering an injected vaccine to wild animals make an oral, bait-delivered form of the vaccine highly desirable. Evaluation of the safety of oral BCG to badgers and the environment is a mandatory step on the road to licensing an oral vaccine. This study had the following objectives: (a) to determine whether adverse effects followed the oral administration of BCG vaccine to badgers; (b) to measure the quantity and frequency of BCG excreted in the faeces of vaccinated badgers; and (c) to assess whether there was evidence of the vaccine spreading to unvaccinated, 'sentinel' badgers sharing the same environment as vaccinated animals. We report here that the oral administration per badger of ≥6.4 × 109 cfu BCG, followed 14 days later by a single oral dose of ≥6.4 × 107 cfu BCG caused no adverse physical effects and did not affect the social behaviour and feeding habits of the vaccinated animals. BCG was cultured from the faeces of two of nine vaccinated animals (372 cfu/g and 996 cfu/g, respectively) approximately 48 h after the higher dose of BCG was administered and by one of the nine vaccinated animal (80 cfu/g) approximately 24 h after receiving the lower dose of BCG. We found no evidence for the transmission of BCG to unvaccinated, sentinel, badgers housed with the vaccinated animals despite the occasional excretion of BCG in faeces.


Subject(s)
BCG Vaccine/adverse effects , BCG Vaccine/immunology , Mustelidae/immunology , Mycobacterium bovis/immunology , Tuberculosis, Bovine/prevention & control , Administration, Oral , Animals , Animals, Wild , BCG Vaccine/administration & dosage , Body Temperature , Cattle , Disease Reservoirs/microbiology , Female , Immunization , Male , Mustelidae/microbiology , Time Factors , Tuberculosis, Bovine/transmission
3.
PLoS One ; 7(12): e49833, 2012.
Article in English | MEDLINE | ID: mdl-23251352

ABSTRACT

Wildlife is a global source of endemic and emerging infectious diseases. The control of tuberculosis (TB) in cattle in Britain and Ireland is hindered by persistent infection in wild badgers (Meles meles). Vaccination with Bacillus Calmette-Guérin (BCG) has been shown to reduce the severity and progression of experimentally induced TB in captive badgers. Analysis of data from a four-year clinical field study, conducted at the social group level, suggested a similar, direct protective effect of BCG in a wild badger population. Here we present new evidence from the same study identifying both a direct beneficial effect of vaccination in individual badgers and an indirect protective effect in unvaccinated cubs. We show that intramuscular injection of BCG reduced by 76% (Odds ratio = 0.24, 95% confidence interval (CI) 0.11-0.52) the risk of free-living vaccinated individuals testing positive to a diagnostic test combination to detect progressive infection. A more sensitive panel of tests for the detection of infection per se identified a reduction of 54% (Odds ratio = 0.46, 95% CI 0.26-0.88) in the risk of a positive result following vaccination. In addition, we show the risk of unvaccinated badger cubs, but not adults, testing positive to an even more sensitive panel of diagnostic tests decreased significantly as the proportion of vaccinated individuals in their social group increased (Odds ratio = 0.08, 95% CI 0.01-0.76; P = 0.03). When more than a third of their social group had been vaccinated, the risk to unvaccinated cubs was reduced by 79% (Odds ratio = 0.21, 95% CI 0.05-0.81; P = 0.02).


Subject(s)
Disease Reservoirs/veterinary , Mustelidae/immunology , Tuberculosis Vaccines , Tuberculosis/veterinary , Vaccination/veterinary , Animals , Cattle , Mycobacterium bovis/immunology , Tuberculosis/prevention & control , Tuberculosis, Bovine/prevention & control
4.
PLoS One ; 6(9): e24636, 2011.
Article in English | MEDLINE | ID: mdl-21931787

ABSTRACT

Upregulation and activation of developmental axon guidance molecules, such as semaphorins and members of the Eph receptor tyrosine kinase family and their ligands, the ephrins, play a role in the inhibition of axonal regeneration following injury to the central nervous system. Previously we have demonstrated in a knockout model that axonal regeneration following spinal cord injury is promoted in the absence of the axon guidance protein EphA4. Antagonism of EphA4 was therefore proposed as a potential therapy to promote recovery from spinal cord injury. To further assess this potential, two soluble recombinant blockers of EphA4, unclustered ephrin-A5-Fc and EphA4-Fc, were examined for their ability to promote axonal regeneration and to improve functional outcome following spinal cord hemisection in wildtype mice. A 2-week administration of either of these blockers following spinal cord injury was sufficient to promote substantial axonal regeneration and functional recovery by 5 weeks following injury. Both inhibitors produced a moderate reduction in astrocytic gliosis, indicating that much of the effect of the blockers may be due to promotion of axon growth. These studies provide definitive evidence that soluble inhibitors of EphA4 function offer considerable therapeutic potential for the treatment of spinal cord injury and may have broader potential for the treatment of other central nervous system injuries.


Subject(s)
Axons/physiology , Nerve Regeneration/drug effects , Receptor, EphA4/metabolism , Recombinant Proteins/therapeutic use , Recovery of Function/drug effects , Spinal Cord Injuries/drug therapy , Animals , Axons/drug effects , Axons/metabolism , Immunoglobulin Fc Fragments/genetics , Immunoglobulin Fc Fragments/metabolism , Immunohistochemistry , Mice , Mice, Inbred C57BL , Receptor, EphA4/antagonists & inhibitors , Recombinant Proteins/genetics , Recombinant Proteins/metabolism
5.
Proc Biol Sci ; 278(1713): 1913-20, 2011 Jun 22.
Article in English | MEDLINE | ID: mdl-21123260

ABSTRACT

Control of bovine tuberculosis (TB) in cattle has proven particularly challenging where reservoirs of infection exist in wildlife populations. In Britain and Ireland, control is hampered by a reservoir of infection in Eurasian badgers (Meles meles). Badger culling has positive and negative effects on bovine TB in cattle and is difficult, costly and controversial. Here we show that Bacillus Calmette-Guérin (BCG) vaccination of captive badgers reduced the progression, severity and excretion of Mycobacterium bovis infection after experimental challenge. In a clinical field study, BCG vaccination of free-living badgers reduced the incidence of positive serological test results by 73.8 per cent. In common with other species, BCG did not appear to prevent infection of badgers subjected to experimental challenge, but did significantly reduce the overall disease burden. BCG vaccination of badgers could comprise an important component of a comprehensive programme of measures to control bovine TB in cattle.


Subject(s)
BCG Vaccine/therapeutic use , Disease Reservoirs/veterinary , Mustelidae/immunology , Tuberculosis, Bovine/prevention & control , Animals , BCG Vaccine/immunology , Cattle , England , Mustelidae/blood , Mustelidae/microbiology , Mycobacterium bovis/immunology , Mycobacterium bovis/pathogenicity , Tuberculosis, Bovine/transmission
6.
Psychoneuroendocrinology ; 31(8): 958-64, 2006 Sep.
Article in English | MEDLINE | ID: mdl-16890375

ABSTRACT

Developmental vitamin D deficiency (DVD) has been shown to alter the orderly pattern of brain development. Even though the period of vitamin D deficiency is restricted to gestation this is sufficient to induce behavioural abnormalities in the adult offspring consistent with those seen in many animal models of schizophrenia. Given that some of these behavioural alterations could also be an indirect result of either impaired maternal hypothalamic pituitary axis (HPA) function (which in turn could influence maternal care) or the result of a permanent alteration in HPA function in the adult offspring we have examined HPA status in both maternal animals and adult offspring. In this study we have established that HPA function is normal in the maternally vitamin D deficient rat. We replicate the behavioural phenotype of hyperlocomotion whilst establishing that HPA function is also unchanged in the adult male offspring. We conclude that the behavioural alterations induced by DVD deficiency are due to some adverse event in brain development rather than via an alteration in stress response.


Subject(s)
Behavior, Animal/physiology , Hypothalamo-Hypophyseal System/physiology , Vitamin D Deficiency/psychology , Animals , Corticosterone/blood , Down-Regulation , Female , Hippocampus/physiology , Male , Motor Activity/physiology , Phenotype , Pregnancy , Prenatal Exposure Delayed Effects , Rats , Rats, Sprague-Dawley , Receptors, Glucocorticoid/metabolism , Restraint, Physical
SELECTION OF CITATIONS
SEARCH DETAIL
...